287 related articles for article (PubMed ID: 25245372)
1. PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention.
Zhu X; Ma X; Hu Y
Curr Med Chem; 2016; 23(17):1756-74. PubMed ID: 25245372
[TBL] [Abstract][Full Text] [Related]
2. Avoid the trap: Targeting PARP1 beyond human malignancy.
Kim C; Chen C; Yu Y
Cell Chem Biol; 2021 Apr; 28(4):456-462. PubMed ID: 33657415
[TBL] [Abstract][Full Text] [Related]
3. An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy.
Wang YQ; Wang PY; Wang YT; Yang GF; Zhang A; Miao ZH
J Med Chem; 2016 Nov; 59(21):9575-9598. PubMed ID: 27416328
[TBL] [Abstract][Full Text] [Related]
4. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
Jain PG; Patel BD
Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
[TBL] [Abstract][Full Text] [Related]
5. Novel tricyclic poly (ADP-ribose) polymerase-1/2 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis and biological evaluation.
Li H; Hu Y; Wang X; He G; Xu Y; Zhu Q
Bioorg Med Chem; 2016 Oct; 24(19):4731-4740. PubMed ID: 27561983
[TBL] [Abstract][Full Text] [Related]
6. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
Chen W; Guo N; Qi M; Dai H; Hong M; Guan L; Huan X; Song S; He J; Wang Y; Xi Y; Yang X; Shen Y; Su Y; Sun Y; Gao Y; Chen Y; Ding J; Tang Y; Ren G; Miao Z; Li J
Eur J Med Chem; 2017 Sep; 138():514-531. PubMed ID: 28692916
[TBL] [Abstract][Full Text] [Related]
7. Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization.
Karche NP; Bhonde M; Sinha N; Jana G; Kukreja G; Kurhade SP; Jagdale AR; Tilekar AR; Hajare AK; Jadhav GR; Gupta NR; Limaye R; Khedkar N; Thube BR; Shaikh JS; Rao Irlapati N; Phukan S; Gole G; Bommakanti A; Khanwalkar H; Pawar Y; Kale R; Kumar R; Gupta R; Praveen Kumar VR; Wahid S; Francis A; Bhat T; Kamble N; Patil V; Nigade PB; Modi D; Pawar S; Naidu S; Volam H; Pagdala V; Mallurwar S; Goyal H; Bora P; Ahirrao P; Singh M; Kamalakannan P; Naik KR; Kumar P; Powar RG; Shankar RB; Bernstein PR; Gundu J; Nemmani K; Narasimham L; George KS; Sharma S; Bakhle D; Kamboj RK; Palle VP
Bioorg Med Chem; 2020 Dec; 28(24):115819. PubMed ID: 33120078
[TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
9. Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule.
Zhao Q; Lan T; Su S; Rao Y
Chem Commun (Camb); 2019 Jan; 55(3):369-372. PubMed ID: 30540295
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of PARP inhibitor sensitivity and resistance.
D'Andrea AD
DNA Repair (Amst); 2018 Nov; 71():172-176. PubMed ID: 30177437
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and evaluation of potential inhibitors for poly(ADP-ribose) polymerase members 1 and 14.
Kam CM; Tauber AL; Levonis SM; Schweiker SS
Future Med Chem; 2020 Dec; 12(24):2179-2190. PubMed ID: 33225736
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
Rajawat J; Shukla N; Mishra DP
Med Res Rev; 2017 Nov; 37(6):1461-1491. PubMed ID: 28510338
[TBL] [Abstract][Full Text] [Related]
13. A DNA-encoded library for the identification of natural product binders that modulate poly (ADP-ribose) polymerase 1, a validated anti-cancer target.
Li J; Li Y; Lu F; Liu L; Ji Q; Song K; Yin Q; Lerner RA; Yang G; Xu H; Ma P
Biochem Biophys Res Commun; 2020 Dec; 533(2):241-248. PubMed ID: 32381359
[TBL] [Abstract][Full Text] [Related]
14. The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy-Current progress and future direction.
Zhao Y; Zhang LX; Jiang T; Long J; Ma ZY; Lu AP; Cheng Y; Cao DS
Eur J Med Chem; 2020 Oct; 203():112570. PubMed ID: 32717529
[TBL] [Abstract][Full Text] [Related]
15. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of novel chrysin derivatives as poly(ADP-ribose) polymerase 1 (PARP1) inhibitors for the treatment of breast cancer.
Yang Y; Tong J; Xie X; Cao H; Fu Y; Luo Y; Liu S; Chen W; Yang N
Chin J Nat Med; 2024 May; 22(5):455-465. PubMed ID: 38796218
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer.
Fu L; Wang S; Wang X; Wang P; Zheng Y; Yao D; Guo M; Zhang L; Ouyang L
Sci Rep; 2016 Dec; 6(1):3. PubMed ID: 28442756
[TBL] [Abstract][Full Text] [Related]
18. [PARP1 inhibitors: contemporary attempts at their use in anticancer therapy and future perspective].
Wiśnik E; Ryksa M; Koter-Michalak M
Postepy Hig Med Dosw (Online); 2016 Apr; 70():280-94. PubMed ID: 27117104
[TBL] [Abstract][Full Text] [Related]
19. High affinity and low PARP-trapping benzimidazole derivatives as a potential warhead for PARP1 degraders.
Peng X; Li Y; Qu J; Jiang L; Wu K; Liu D; Chen Y; Peng J; Guo Y; Cao X
Eur J Med Chem; 2024 May; 271():116405. PubMed ID: 38678823
[TBL] [Abstract][Full Text] [Related]
20. Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers.
Putri JF; Bhargava P; Dhanjal JK; Yaguchi T; Sundar D; Kaul SC; Wadhwa R
J Exp Clin Cancer Res; 2019 Dec; 38(1):499. PubMed ID: 31856867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
